drugset
drugset / Trial / NCT05584202

Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273.214 SARS-CoV-2 (COVID-19) Vaccine in Infants

NCT05584202 ↗

Phase 2 Terminated 68 enrolled ModernaTX, Inc.
RandomizedSequentialQuadruple-blindPrevention

Summary

The study evaluated the safety, tolerability, reactogenicity, and effectiveness of mRNA-1273.214 severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine in infants aged 12 weeks to \< 6 months.

Timeline

Start
2022-09-30
Primary completion
2024-11-15
Completion
2024-11-15

Drugs

EvaluationDrugModalityDoseRoute
Subject mRNA-1273.214 Messenger RNA (mRNA) — Intramuscular

Indications

COVID-19